Acute-on-chronic liver failure (ACLF) occurs in 30% of hospitalized cirrhosis patients, leading to over one million deaths worldwide each year. Currently, the only potential treatment for this condition is liver transplantation, which is available to very few patients. A first-in-human randomized controlled clinical trial using DIALIVE, a novel liver dialysis device, demonstrated its potential as a disease-modifying therapy and resolved liver failure significantly faster and in a greater p.
(2)
The CARBALIVE Consortium announces positive results of a Phase 2 equivalent trial of engineered macroporous carbons as a novel treatment for cirrhosis
Patients treated with orally-administered, non-absorbable engineered carbon of controlled porosity was safe, tolerable and showed trends in improvements in a range of biomarkers of systemic inflammation
The mechanism of this effect is modulation of dysbiosis, gut inflammation and leaky gut that are characteristic of cirrhosis
Planning for pivotal trials to support approval in Europe is now under way
7
th January, 2021 - The
CARBALIVE Consortium( CARBALIVE or the Consortium ) is pleased to announce positive data from the Phase 2 equivalent randomised, double-blind clinical trial of Carbalive, a product candidate for the treatment of patients with decompensated cirrhosis. Carbalive is specifically designed to remove harmful bacterial toxins from the gut, reduce gut inflammation and its permeability, preventing them from